BioSpace News Archive

PTC Therapeutics reported Q4 and full-year 2022 results Tuesday ahead of a pivotal 2023 featuring three late-stage readouts in registration-directed trials.

Rubius Therapeutics’ board of directors has approved a plan to liquidate and dissolve the company, the Massachusetts-based biotech announced in an SEC form 8-K filed Monday.

After overcoming a clinical hold, Astellas presented preliminary safety and efficacy data from the Phase I/II FORTIS trial of AT845 in late-onset Pompe disease at the 19th Annual WORLDSymposium 2023.

Some consider a candidate’s alma mater to be the most important factor in the hiring process. But how much does a life science candidate’s alma mater really matter? In short–it depends.

Life Edit’s technology will combine with Moderna’s mRNA platform to develop in vivo gene editing therapeutics against thus far undisclosed challenging genetic diseases.

New York City employers who use Artificial Intelligence (AI) tools in hiring will soon be subject to new regulations requiring them to notify candidates when using the technology.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19th Annual WORLDSymposium™, taking place from February 22-26, 2023, in Orlando, Florida.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:50 a.m. PT / 12:50 p.m. ET.

VolitionRx Limited announced the closing of its previously announced underwritten public offering of 4,945,000 shares of its common stock, including the exercise in full of the underwriter’s overallotment option, at a public offering price of $1.75 per share.

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended December 31, 2022.